KRAS and breast cancer: When comparing the patient population of those harboring KRAS activating mutations or amplifications, which account for 2.2% of all breast cancer cases, we find a marked decrease in overall survival compared to the unaltered cohort (Fig. 7D) with median overall survival at 77.7-months (95% CI: 61.8–146.4) for the KRAS altered population compared to median overall survival of 164.3 months (95% CI: 154.3–173.0) for the unaltered cohort (Additional files 33 and 34: Tables S8 and S9).